Investor's Business Daily on MSN
AbbVie flails as 'negative sentiment' persists despite immunology beat
AbbVie stock yo-yoed Wednesday after its immunology blockbusters helped offset a continued decline for Humira.
Zacks Investment Research on MSN
ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View
AbbVie Inc. ABBV reported first-quarter 2026 adjusted EPS of $2.65, which beat the Zacks Consensus Estimate of $2.62. The ...
"Actresses without Botox are quickly becoming an endangered species," a podcaster wrote in a post viewed 9 million times.
New data show early and sustained weight loss with atogepant, raising the possibility of metabolic benefits beyond migraine prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results